🇺🇸 FDA
Pipeline program

Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln

WA41937

Phase 3 small_molecule active

Quick answer

Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln for Primary Membranous Nephropathy (pMN) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Primary Membranous Nephropathy (pMN)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials